Browse categories and answer follow-up questions to refine your symptom profile.
Approach to the Critical Patient
Immediate priorities
Immediate stabilization
Airway patency and aspiration risk
If vomiting and reduced consciousness then airway protection
Breathing and oxygenation
Oxygen for hypoxemia
Circulation and perfusion
Large bore IV access times 2
Continuous cardiac monitoring
Defibrillator pads in place
Rapid 12 lead ECG
Repeat ECG after any rhythm change
Point of care glucose
Hypoglycemia correction
High risk features
Ventricular tachycardia or ventricular fibrillation
Urgent digoxin specific Fab
High grade AV block
Urgent digoxin specific Fab
Hemodynamic instability
Urgent digoxin specific Fab
Hyperkalemia in suspected cardiac glycoside poisoning
Urgent digoxin specific Fab
Team activation
Poison centre or medical toxicology consult early
Early antidote coordination and dosing strategy
Cardiology consult for unstable conduction disease
Temporary pacing planning
Evidence and guidelines
Digoxin specific Fab for life threatening cardiac glycoside poisoning
AHA focused update supports administration in life threatening poisoning Class I
Evidence base heterogeneous and dosing varies by region
When ACEP policy absent use expert consensus framework ACEP Level C
Monitoring and targets
Monitoring bundle
Continuous ECG rhythm and rate trends
Intermittent 12 lead ECG for evolving block or ectopy
Frequent blood pressure
Arterial line for shock or vasopressors
Strict input output
Urinary catheter for shock or severe toxicity
Physiologic targets
Adequate perfusion
Mentation improving
Capillary refill improving
Urine output improving
Electrolyte targets
Potassium 4.0 to 5.0 mmol/L
Magnesium at upper normal range
Initial antidote readiness
Digoxin specific Fab readiness
Immediate pharmacy notification
Stock check and rapid delivery
Reconstitution and infusion plan
Anaphylaxis preparedness
Post Fab monitoring plan
Rebound toxicity surveillance
History
Exposure characterization
Exposure details
Digoxin formulation
Tablet dose in mg
Capsule dose in mg
Liquid dose and concentration
Timing
Time of last therapeutic dose
Time of suspected overdose
Intent
Medication error
Drug interaction
Renal function decline
Ingestion of plants or toxins
Co exposures
AV nodal blockers
Beta blocker
Non dihydropyridine calcium channel blocker
Antiarrhythmics
Amiodarone
Quinidine
Propafenone
Antibiotics and antifungals
Macrolide
Azole
Diuretics and electrolytes
Loop diuretic
Thiazide diuretic
Recent hypokalemia or hypomagnesemia
Symptom pattern
Typical symptoms
Nausea
Persistent vomiting
Abdominal pain
Poor oral intake and dehydration
Dizziness and presyncope
Palpitations
Confusion or delirium
Lethargy
Visual disturbance
Blurred vision
Color vision change
Pitfall presentations
Minimal symptoms with dangerous ECG changes
Older adults and renal impairment
Risk factors
Patient risk
Older age
Lower volume of distribution and higher sensitivity
Chronic kidney disease
Reduced clearance
Heart failure
Polypharmacy and electrolyte shifts
Hypothyroidism
Higher serum levels at same dose
Cardiac glycoside sources
Foxglove ingestion
Plant identification uncertainty
Oleander ingestion
Tea or herbal preparation
Toad venom exposure
Bufadienolide exposure history
Physical Exam
Core exam domains
Hemodynamic status
Bradycardia
Perfusion signs
Hypotension
Shock index trend
Irregular rhythm
Variable pulse deficit
Neurologic status
Mental status
Confusion
Agitation
Reduced level of consciousness
Pupils
Alternate causes of delirium
Volume status
Dehydration signs
Dry mucosa
Orthostasis
Heart failure signs
Pulmonary edema
Peripheral edema
GI findings
Ongoing emesis
Aspiration risk
Abdominal tenderness
Alternate diagnosis consideration
ECG linked bedside findings
Conduction disease signs
Cannon A waves
AV dissociation consideration
Variable intensity S1
Complete heart block consideration
Perfusion threats
Chest pain or dyspnea
Ischemia or pulmonary edema
Differential Diagnosis
Life threatening mimics
Bradyarrhythmia and shock differential
Beta blocker toxicity ICD-10 T44.7X1A
Hypoglycemia and bronchospasm clues
Calcium channel blocker toxicity ICD-10 T46.1X1A
Hyperglycemia clue
Hyperkalemia due to renal failure ICD-10 E87.5
Severe metabolic acidosis clue
Sick sinus syndrome ICD-10 I49.5
History of pauses
Inferior myocardial infarction ICD-10 I21.19
ST elevation in inferior leads
Ventricular ectopy differential
Acute coronary syndrome ICD-10 I24.9
Troponin and ischemic ECG changes
Polymorphic VT due to long QT ICD-10 I47.2
QT prolongation drivers
Sympathomimetic toxicity ICD-10 T43.601A
Hypertension and agitation
Non cardiac contributors
Altered mental status differential
Sepsis ICD-10 A41.9
Fever and hypotension
Medication toxicity other than digoxin
Sedative hypnotic effect
Hypoxia
Respiratory failure
Laboratory Tests
Immediate labs
Initial laboratory panel
Basic metabolic panel
Potassium for severity and Fab indication
Creatinine for clearance prediction
Bicarbonate for acid base status
Magnesium
Hypomagnesemia correction target
Calcium
Baseline value for hyperkalemia algorithms
Venous blood gas
pH for arrhythmia risk
Lactate for shock severity
Glucose
Co ingestion screen
Cardiac injury labs
Troponin
Concurrent ischemia consideration
BNP or NT proBNP
Heart failure assessment
Digoxin level interpretation
Serum digoxin concentration
Timing considerations
Levels within 6 hours after acute ingestion may not reflect tissue distribution
Level for dosing calculations ideally after 6 hours
Chronic toxicity caveats
Serum level may be within therapeutic range with clinical toxicity
Post Fab caveats
Total digoxin level rises after Fab and is not a toxicity marker
Clinical status and free digoxin assays if available
Unit conversion support
Digoxin nmol/L times 0.781 equals digoxin ng/mL
Additional tests by scenario
Co ingestion screen
Acetaminophen level
Unknown ingestion history
Salicylate level
Mixed overdose possibility
Hematology
Complete blood count
Infection or anemia contribution
Pregnancy test
Reproductive age patient
Diagnostic Tests
Scoring Systems
Severity and antidote criteria
Life threatening toxicity indicators
Ventricular tachycardia or ventricular fibrillation
Asystole or pulseless electrical activity with suspected glycoside poisoning
Symptomatic bradycardia with high grade AV block
Hypotension or shock attributed to digoxin effect
Hyperkalemia in suspected acute cardiac glycoside poisoning
Antidote dosing calculation pathways
If ingested dose known
Vials equals digoxin dose ingested in mg times 0.8
Each vial binds 0.5 mg digoxin equivalent
If serum concentration and weight available
Formula option A US package insert vials equals serum digoxin ng/mL times weight kg divided by 100
Formula option B EU SmPC vials equals serum digoxin ng/mL times weight kg divided by 200
Poison centre guidance for local standardization
Evidence levels
Digoxin Fab administration for life threatening poisoning Class I
Temporary pacing while awaiting Fab effect Class IIa
Lidocaine or phenytoin for ventricular dysrhythmias while awaiting Fab effect Class IIb
MRI
MRI use cases
Neurologic deficit not explained by toxicity
Stroke evaluation
Contraindications consideration
Unstable patient and monitoring limitations
CT
CT use cases
Altered mental status with trauma or focal deficit
CT head noncontrast
Abdominal catastrophe concern
CT abdomen pelvis with contrast if stable
Pulmonary edema alternative diagnosis
CT pulmonary angiography if PE concern and stable
Ultrasound
Bedside ultrasound
Shock evaluation
Cardiac function gross assessment
Pericardial effusion
Volume status evaluation
IVC variability interpretation
Pulmonary edema evaluation
B lines pattern
Disposition
Level of care decisions
ICU indications
Digoxin specific Fab administration
Rebound toxicity monitoring
Ventricular dysrhythmia
Antiarrhythmic infusion requirement
High grade AV block
Pacing requirement
Significant hyperkalemia
Serial potassium and ECG monitoring
Hemodynamic instability
Vasopressor requirement
Telemetry admission indications
Symptomatic toxicity without ICU criteria
Persistent GI symptoms
Mild conduction abnormalities
Electrolyte derangements requiring IV replacement
Hypokalemia or hypomagnesemia
Discharge considerations
Discharge criteria for mild cases
Normal vital signs and stable rhythm
No high grade AV block
Symptoms resolved
No ongoing vomiting
Electrolytes normalized
Potassium and magnesium stable
Clear medication plan
Digoxin held and follow up arranged
Treatment
Antidote and definitive therapy
Digoxin specific immune Fab
Indications
Ventricular tachycardia or ventricular fibrillation
Class I
Symptomatic bradycardia with high grade AV block
Class I
Cardiac arrest attributed to cardiac glycoside poisoning
Class I
Hyperkalemia with suspected acute cardiac glycoside poisoning
Class I
Dosing by known ingestion
Vials equals digoxin dose ingested in mg times 0.8
Tablet bioavailability assumption 0.8
Full neutralization option vials equals total body load mg divided by 0.5
Each vial binds 0.5 mg digoxin equivalent
Dosing by serum level and weight
Formula option A US package insert
Vials equals serum digoxin ng/mL times weight kg divided by 100
Formula option B EU SmPC
Vials equals serum digoxin ng/mL times weight kg divided by 200
Conversion support
Digoxin nmol/L times 0.781 equals digoxin ng/mL
Administration
Initiate infusion over at least 30 minutes if stable
Slower rate if infusion reaction
If cardiac arrest then bolus dosing strategy per local protocol
Repeat dose after 15 to 30 minutes if inadequate response
Adverse effects and monitoring
Anaphylaxis and infusion reaction readiness
Epinephrine and airway equipment available
Worsening heart failure due to loss of inotropy
Diuresis and oxygen support as needed
Hypokalemia after reversal
Frequent potassium monitoring
Supportive care and decontamination
Decontamination for acute ingestion
Activated charcoal single dose
1 g/kg PO or NG
Typical adult dose 50 g
Airway protection prerequisite
Activated charcoal multiple dose
Consider for massive ingestion or prolonged absorption
0.5 g/kg every 4 hours
Ileus and aspiration risk monitoring
Fluids
Isotonic crystalloid for dehydration
Cautious in heart failure
Electrolyte correction
Potassium repletion in hypokalemia
Slow IV replacement with telemetry
Avoid overcorrection in chronic toxicity
Magnesium sulfate for hypomagnesemia
2 g IV over 10 to 20 minutes
Repeat dosing to upper normal range
Bradyarrhythmia management while awaiting Fab
Atropine
Initiate 1 mg IV
Repeat every 3 to 5 minutes
Maximum 3 mg
Limited efficacy in infranodal block
Early pacing planning
Transcutaneous pacing
If unstable bradycardia refractory to atropine
Analgesia and sedation if time allows
Transvenous pacing
If persistent high grade AV block with instability
Cardiology support
Ventricular dysrhythmia management while awaiting Fab
Lidocaine
Initiate 1 to 1.5 mg/kg IV bolus
Repeat 0.5 to 0.75 mg/kg every 5 to 10 minutes
Maximum 3 mg/kg
Infusion
Initiate 1 to 4 mg per minute
Phenytoin
Initiate 15 mg/kg IV
Maximum infusion rate 50 mg per minute
Hypotension monitoring
Electrical therapy caveats
Synchronized cardioversion for unstable VT
Use lowest effective energy
Fab prioritized when available
Defibrillation for VF or pulseless VT
Standard ACLS energy
Avoided or caution agents
Amiodarone
Can increase digoxin levels and worsen toxicity
Procainamide
Hypotension and conduction worsening concern
Quinidine
Potent digoxin level increase
Hyperkalemia in suspected cardiac glycoside poisoning
Antidote first strategy
Digoxin specific Fab as definitive therapy
Potassium reduction expected after reversal
Temporizing measures
Insulin regular 10 units IV
Dextrose 25 g IV if glucose less than 11 mmol/L
Glucose monitoring every 30 to 60 minutes
Nebulized albuterol 10 to 20 mg
Tachycardia monitoring
Sodium bicarbonate 50 mmol IV
Consider if metabolic acidosis
Calcium salts
Controversial historical avoidance
If immediately life threatening ECG instability and Fab not immediately available then consider calcium with toxicology guidance
Potassium removal
Loop diuretic if adequate renal function
Volume status monitoring
Potassium binders
Delayed onset
Dialysis
For refractory hyperkalemia due to renal failure
Digoxin removal limited
Special Populations
Pregnancy
Pregnancy considerations
Maternal stabilization priority
Continuous fetal monitoring if viable gestation and stable maternal status
Digoxin specific Fab use
Use for maternal life threatening toxicity
Placental transfer considerations and specialist input
Hyperkalemia management
Same physiologic principles with obstetric coordination
Geriatric
Older adult considerations
Chronic toxicity predominance
Nonspecific symptoms and delirium
Renal clearance reduction
Lower threshold for Fab in instability
Polypharmacy interaction burden
Medication reconciliation emphasis
Higher pacing risk
Early cardiology involvement
Pediatrics
Pediatric considerations
Weight based dosing for all therapies
Activated charcoal 1 g/kg
Digoxin specific Fab dosing
Use calculated vial fraction strategies when very small doses required
Dilution to 1 mg/mL approach for small volume administration
Plant ingestion risk
Oleander and foxglove exposure suspicion
Poison centre consultation mandatory
Regional antidote availability and dosing standardization
Background
Epidemiology
Epidemiology
Narrow therapeutic index drug exposure
Toxicity risk increases with renal impairment and drug interactions
Chronic toxicity more common than acute overdose
Older adults and heart failure populations
Non pharmaceutical glycoside exposures
Oleander and foxglove
Bufo toad venom
Pathophysiology
Mechanism
Na K ATPase inhibition
Increased intracellular sodium
Increased intracellular calcium via Na Ca exchange
Increased vagal tone
AV nodal conduction slowing
Arrhythmogenesis
Increased automaticity
Triggered activity
Electrolyte interactions
Hypokalemia increases binding and toxicity
Higher arrhythmia risk
Hyperkalemia in acute overdose
Marker of severe Na K ATPase blockade
Hypomagnesemia potentiates dysrhythmias
Replacement reduces ectopy risk
Therapeutic Considerations
Digoxin specific Fab rationale
Antibody fragment binding to free digoxin
Redistribution from tissues to serum and renal elimination
Clinical response timing
Rhythm and hemodynamics may improve within 30 to 60 minutes
Serum digoxin interpretation after Fab
Total levels increase and lose clinical correlation
Antiarrhythmic selection rationale
Lidocaine and phenytoin preferred while awaiting Fab effect
Limited data support per AHA focused update
Evidence grading framework
Life threatening poisoning management anchored to AHA Class recommendations
Use ACEP Level C for expert consensus steps without high quality trials
Patient Discharge Instructions
copy discharge instructions
Discharge instructions
Digoxin hold plan
Do not restart unless explicitly instructed
Medication list review
Avoid new interacting medications unless prescriber aware
Hydration guidance
Maintain oral fluids if not restricted for heart failure
Follow up plan
Primary prescriber within 24 to 72 hours
Lab recheck plan for potassium and creatinine
Return to emergency care immediately
Fainting or near fainting
Chest pain
New shortness of breath
Persistent vomiting
New confusion
Palpitations
Slow heart rate symptoms
Severe weakness
References
Key sources
Clinical guidelines and consensus
American Heart Association focused update on poisoning related cardiac arrest and life threatening toxicity 2023
Digoxin specific Fab recommended for life threatening cardiac glycoside poisoning
DIGIFab EU SmPC June 2024
Dosing options including vials equals serum digoxin ng/mL times weight kg divided by 200
Conversion digoxin nmol/L times 0.781 equals digoxin ng/mL
DIGIFAB FDA package insert
Chronic toxicity dosing vials equals serum digoxin ng/mL times weight kg divided by 100
Acute ingestion dosing based on total body load and 0.8 tablet bioavailability
Evidence based summaries
NCBI StatPearls Digoxin immune Fab updated 2024
Indications and monitoring considerations
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.